Skip to content
ChickenStockChickenStock
ResearchMLTX
Moonlake Immunotherapeutics logo

Moonlake Immunotherapeutics (MLTX) stock

NASDAQ

$11.26-4.01%(-0.47)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-3.49x

Net loss — not comparable

P/B

2.51x

P/S

—

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 4, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

5 SEC filings
  • Reich KristianChief Scientific Officer · Jul 27, 2026Open-market sale1,100 shares · $22K
    Avg. price $202,711,198 shares held after
  • Reich KristianChief Scientific Officer · Jul 22, 2026Open-market sale2,448 shares · $49K
    Avg. price $202,712,298 shares held after
  • Reich KristianChief Scientific Officer · Jul 21, 2026Open-market sale50,000 shares · $1.0M
    Avg. price $20.022,714,746 shares held after
  • Reich KristianChief Scientific Officer · Jul 20, 2026Open-market sale43,700 shares · $878K
    Avg. price $20.092,764,746 shares held after
  • Reich KristianChief Scientific Officer · Jul 15, 2026Open-market sale16,105 shares · $322K
    Avg. price $20.012,808,446 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Moonlake Immunotherapeutics (MLTX) stock information

NASDAQ

Moonlake Immunotherapeutics (MLTX) is listed on NASDAQ. Its market capitalization is about $957M. On trailing-twelve-month earnings the P/E ratio is -3.49, and the P/B ratio is 2.51. Return on equity is -71.7%. These figures are computed in-house from official filings and are reference information only.

Moonlake Immunotherapeutics — frequently asked questions

What is the P/E ratio of Moonlake Immunotherapeutics (MLTX)?
On a trailing-twelve-month basis, MLTX trades at a P/E ratio of -3.49. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Moonlake Immunotherapeutics?
MLTX has a market capitalization of about $957M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.